You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrimethoprim
Accession NumberDB00440  (APRD00103)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to pyrimethamine. The interference with folic acid metabolism may cause a depression of hematopoiesis. It is potentiated by sulfonamides and the trimethoprim-sulfamethoxazole combination is the form most often used. It is sometimes used alone as an antimalarial. Trimethoprim resistance has been reported. [PubChem]
Structure
Thumb
Synonyms
2,4-Diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
5-[(3,4,5-Trimethoxyphenyl)methyl]-2,4-pyrimidinediamine
Proloprim
Trimethoprim
Triméthoprime
Trimethoprimum
Trimetoprima
Trimpex
External Identifiers
  • BW 56-72
  • Ro 6-2153-12 F
  • UNII-9XE000OU9B
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Primsolsolution50 mg/5mLoralFSC Laboratories, Inc2000-01-24Not applicableUs
Primsolsolution50 mg/5mLoralAytu Bio Science, Inc.2015-09-15Not applicableUs
Proloprim 200 Tab 200mgtablet200 mgoralGlaxosmithkline Inc1985-12-312004-08-05Canada
Proloprim Tab 100mgtablet100 mgoralGlaxosmithkline Inc1986-12-312003-10-28Canada
Trimethoprimtablet100 mg/1oralTeva Pharmaceuticals USA Inc1990-09-30Not applicableUs
Trimethoprim Tabletstablet200 mgoralAa Pharma Inc2001-07-30Not applicableCanada
Trimethoprim Tabletstablet100 mgoralAa Pharma Inc2001-01-01Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Trimethoprimtablet100 mg/1oralCarilion Materials Management2010-04-04Not applicableUs
Trimethoprimtablet100 mg/1oralWatson Laboratories, Inc.2010-04-04Not applicableUs
Trimethoprimtablet100 mg/1oralAv Pak2013-07-31Not applicableUs
Trimethoprimtablet100 mg/1oralNovel Laboratories, Inc.2011-06-24Not applicableUs
Trimethoprimtablet100 mg/1oralREMEDYREPACK INC.2013-09-24Not applicableUs
Trimethoprimtablet100 mg/1oralAv Kare, Inc.2013-05-06Not applicableUs
Trimethoprimtablet100 mg/1oralPhysicians Total Care, Inc.2012-05-02Not applicableUs
Trimethoprimtablet100 mg/1oralGAVIS Pharmaceuticals, LLC2011-06-24Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlprimAlphapharm
CatinKojar
EumiHwang's
InflamnilSwiss Pharm
LannacherRoot
LariagoIpca Laboratories
MeprimJohnson
MetipineKojar
MonotrimGlaxoSmithKline
MotrimLannacher
ProloprimGlaxoSmithKline
TrimpexNot Available
TriprimGlaxoSmithKline
Brand mixtures
NameLabellerIngredients
Apo Sulfatrim DS TabApotex Inc
Apo Sulfatrim PediatricApotex Inc
Apo Sulfatrim TabApotex Inc
Apo-sulfatrim Oral SuspensionApotex Inc
BactrimAR Scientific, Inc.
Bactrim DSAR Scientific, Inc.
Bactrim DS Roche TabHoffmann La Roche Limited
Bactrim Roche InjHoffmann La Roche Limited
Bactrim Roche Suspension PaediatricHoffmann La Roche Limited
Bactrim Roche TabHoffmann La Roche Limited
Coptin Oral SuspensionAxcan Pharma Inc
Coptin TabPfizer Canada Inc
Nu-cotrimox Sus 40/8mg/mlNu Pharm Inc
Nu-cotrimox Tab 400/80mgNu Pharm Inc
Nu-cotrimox-DS Tab 800/160mgNu Pharm Inc
PMS-polytrimethoprimPharmascience Inc
Polymyxin B Sulfate and TrimethoprimSTAT RX LLC USA
Polymyxin B Sulfate and Trimethoprim SulfateMedsource Pharmaceuticals
PolytrimAllergan, Inc.
Polytrim Ophthalmic SolutionAllergan Inc
Protrin Df TabPro Doc Limitee
Protrin TabPro Doc Limitee
Riva-sep DSLaboratoire Riva Inc
Roubac Tab 160/800Rougier Pharma Division Of Ratiopharm Inc
Roubac Tab 80/400Rougier Pharma Division Of Ratiopharm Inc
Sandoz PolytrimethoprimSandoz Canada Incorporated
SeptraGlaxosmithkline Inc
Septra DS TabletsGlaxosmithkline Inc
Septra InjectionAspen Pharma Trading Limited
Septra Pediatric SuspensionGlaxosmithkline Inc
Sulfamethoxazole and TrimethoprimTeva Pharmaceuticals USA Inc
Sulfamethoxazole and Trimethoprim (double Strength)Teva Pharmaceuticals USA Inc
Sulfamethoxazole and Trimethoprim Double StrengthLake Erie Medical Dba Quality L Care Products Lc
Sulfamethoxazole and Trimethoprim DSApotheca Inc.
Sulfamethoxazole and Trimethoprim TabletsD.C. Labs Limited
SulfatrimSTI Pharma LLC
Teva-trimelTeva Canada Limited
Teva-trimel DSTeva Canada Limited
Trimethoprim Sulfate and Polymyxin B SulfateAkorn, Inc.
Trisulfa DS TabJaapharm Canada Inc.
Trisulfa S SuspensionJaapharm Canada Inc.
Trisulfa TabJaapharm Canada Inc.
Salts
Name/CASStructureProperties
Trimethoprim hydrochloride
ThumbNot applicableDBSALT001480
Trimethoprim sulfate
ThumbNot applicableDBSALT001471
Categories
UNIIAN164J8Y0X
CAS number738-70-5
WeightAverage: 290.3177
Monoisotopic: 290.137890462
Chemical FormulaC14H18N4O3
InChI KeyInChIKey=IEDVJHCEMCRBQM-UHFFFAOYSA-N
InChI
InChI=1S/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)
IUPAC Name
5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
SMILES
COC1=CC(CC2=CN=C(N)N=C2N)=CC(OC)=C1OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentAnisoles
Alternative Parents
Substituents
  • Anisole
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Pyrimidine
  • Primary aromatic amine
  • Heteroaromatic compound
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of urinary tract infections, uncomplicated pyelonephritis (with sulfamethoxazole) and mild acute prostatitis. May be used as pericoital (with sulfamethoxazole) or continuous prophylaxis in females with recurrent cystitis. May be used as an alternative to treat asymptomatic bacteriuria during pregnancy (only before the last 6 weeks of pregnancy). Other uses include: alternative agent in respiratory tract infections (otitis, sinusitus, bronchitis and pneumonia), treatment of Pneumocystis jirovecii pneumonia (acute or prophylaxis), Nocardia infections, and traveller's diarrhea.
PharmacodynamicsTrimethoprim is a pyrimidine analogue that disrupts folate synthesis, an essential part of the thymidine synthesis pathway. Inhibition of the enzyme starves the bacteria of nucleotides necessary for DNA replication.The drug, therefore, exhibits bactericidal activity.
Mechanism of actionTrimethoprim binds to dihydrofolate reductase and inhibits the reduction of dihydrofolic acid (DHF) to tetrahydrofolic acid (THF). THF is an essential precursor in the thymidine synthesis pathway and interference with this pathway inhibits bacterial DNA synthesis. Trimethoprim's affinity for bacterial dihydrofolate reductase is several thousand times greater than its affinity for human dihydrofolate reductase. Sulfamethoxazole inhibits dihydrofolate synthetase (aka dihydropteroate synthetase), an enzyme involved further upstream in the same pathway. Trimethoprim and sulfamethoxazole are commonly used in combination due to their synergistic effects. This drug combination also reduces the development of resistance that is seen when either drug is used alone.
Related Articles
AbsorptionReadily and almost completely absorbed in the GI tract with peak serum concentrations attained 1-4 hours after oral administration. Widely distributed to tissues and fluids including kidney, lung, seminal fluid, aqueous humour, middle ear fluid, sputum, vaginal secretions, bile, bone and CSF.
Volume of distributionNot Available
Protein binding42-46% bound to plasma proteins
Metabolism

Hepatic metabolism to oxide and hydroxylated metabolites.

Route of eliminationTen to twenty percent of trimethoprim is metabolized, primarily in the liver; the remainder is excreted unchanged in the urine. After oral administration, 50% to 60% of trimethoprim is excreted in the urine within 24 hours, approximately 80% of this being unmetabolized trimethoprim. Trimethoprim also passes the placental barrier and is excreted in human milk.
Half life8-11 hours in adults with normal renal function
ClearanceNot Available
ToxicityLD50=4850 (orally in mice)
Affected organisms
  • Gram negative and gram positive bacteria
  • Listeria monocytogenes
  • Escherichia coli
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.994
Blood Brain Barrier+0.9381
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5845
P-glycoprotein inhibitor INon-inhibitor0.8631
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.8531
CYP450 2C9 substrateNon-substrate0.8799
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5732
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8467
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.8227
CarcinogenicityNon-carcinogens0.9369
BiodegradationNot ready biodegradable0.9949
Rat acute toxicity1.7701 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9394
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Monarch pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Hoffmann la roche inc
  • Fsc laboratories inc
Packagers
Dosage forms
FormRouteStrength
Liquidintravenous
Liquidophthalmic
Solutionophthalmic
Solution/ dropsophthalmic
Solutionoral50 mg/5mL
Solutionintravenous
Injection, solution, concentrateintravenous
Suspensionoral
Tabletoral
Tabletoral100 mg/1
Tabletoral100 mg
Tabletoral200 mg
Prices
Unit descriptionCostUnit
Bactrim ds tablet5.53USD tablet
Bactrim DS 800-160 mg tablet3.0USD tablet
Septra DS 800-160 mg tablet2.43USD tablet
Septra ds tablet2.33USD tablet
Trimethoprim powder1.79USD g
Bactrim 400-80 mg tablet1.63USD tablet
Septra 80-400 tablet1.49USD tablet
Sulfamethoxazole-tmp ds tablet1.44USD tablet
Sulfamethoxazole-tmp vial0.84USD ml
Trimethoprim 100 mg tablet0.7USD tablet
Sulfamethoxazole-Trimethoprim 400-80 mg tablet0.69USD tablet
Apo-Trimethoprim 200 mg Tablet0.55USD tablet
Primsol 50 mg/5 ml oral soln0.39USD ml
Apo-Trimethoprim 100 mg Tablet0.27USD tablet
Sulfamethoxazole-tmp ss tablet0.17USD tablet
Sulfamethoxazole-Trimethoprim 200-40 mg/5ml Suspension0.13USD ml
Sulfatrim 200-40 mg/5ml Suspension0.13USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5763449 No1996-08-072016-08-07Us
US5962461 No1996-08-072016-08-07Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point199-203 °CPhysProp
water solubility400 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.91HANSCH,C ET AL. (1995)
logS-2.86ADME Research, USCD
pKa7.12 (at 20 °C)PERRIN,DD (1972)
Predicted Properties
PropertyValueSource
Water Solubility0.615 mg/mLALOGPS
logP1.26ALOGPS
logP1.28ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)17.33ChemAxon
pKa (Strongest Basic)7.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area105.51 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity81.51 m3·mol-1ChemAxon
Polarizability29.71 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Yasushi Takagishi, Kiichiro Ohsuga, Sadao Ohama, “Suppository containing sulfamethoxazole/trimethoprim complex and process for preparing the same.” U.S. Patent US4461765, issued December, 1975.

US4461765
General References
  1. Brumfitt W, Hamilton-Miller JM: Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines. J Chemother. 1993 Dec;5(6):465-9. [PubMed:8195839 ]
  2. Brumfitt W, Hamilton-Miller JM: Limitations of and indications for the use of co-trimoxazole. J Chemother. 1994 Feb;6(1):3-11. [PubMed:8071675 ]
  3. Bean DC, Livermore DM, Papa I, Hall LM: Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man. J Antimicrob Chemother. 2005 Nov;56(5):962-4. Epub 2005 Sep 8. [PubMed:16150859 ]
  4. Felmingham D, Reinert RR, Hirakata Y, Rodloff A: Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002 Sep;50 Suppl S1:25-37. [PubMed:12239226 ]
  5. Johnson JR, Manges AR, O'Bryan TT, Riley LW: A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis. Lancet. 2002 Jun 29;359(9325):2249-51. [PubMed:12103291 ]
External Links
ATC CodesJ01EA01J01EE05J01EE01J01EE07J01EE03J01EE04J01EE02
AHFS Codes
  • 08:36.00
PDB EntriesNot Available
FDA labelDownload (98.5 KB)
MSDSDownload (74.3 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Trimethoprim can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Trimethoprim.
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Trimethoprim.
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Trimethoprim.
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Trimethoprim.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Trimethoprim.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Trimethoprim.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Trimethoprim.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Trimethoprim.
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Trimethoprim.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Trimethoprim.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Trimethoprim.
AlosetronThe metabolism of Alosetron can be decreased when combined with Trimethoprim.
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Trimethoprim.
AmantadineThe risk or severity of adverse effects can be increased when Trimethoprim is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Trimethoprim.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Trimethoprim.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Trimethoprim.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Trimethoprim.
AmodiaquineTrimethoprim may increase the neutropenic activities of Amodiaquine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Trimethoprim.
AnagrelideTrimethoprim may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Trimethoprim.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Trimethoprim.
AprepitantThe serum concentration of Trimethoprim can be increased when it is combined with Aprepitant.
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Trimethoprim.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Trimethoprim.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Trimethoprim.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Trimethoprim.
ArtemetherThe metabolism of Artemether can be decreased when combined with Trimethoprim.
AsenapineTrimethoprim may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe metabolism of Trimethoprim can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Trimethoprim.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Trimethoprim.
AtomoxetineThe metabolism of Trimethoprim can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Trimethoprim.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Trimethoprim.
AzathioprineTrimethoprim may increase the myelosuppressive activities of Azathioprine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Trimethoprim.
Azilsartan medoxomilTrimethoprim may increase the hyperkalemic activities of Azilsartan medoxomil.
AzithromycinTrimethoprim may increase the QTc-prolonging activities of Azithromycin.
BedaquilineTrimethoprim may increase the QTc-prolonging activities of Bedaquiline.
BenazeprilTrimethoprim may increase the hyperkalemic activities of Benazepril.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Trimethoprim.
BeraprostThe metabolism of Beraprost can be decreased when combined with Trimethoprim.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Trimethoprim.
BexaroteneThe serum concentration of Trimethoprim can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Trimethoprim.
BoceprevirThe metabolism of Trimethoprim can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Trimethoprim.
BortezomibThe metabolism of Trimethoprim can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Trimethoprim can be decreased when it is combined with Bosentan.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Trimethoprim.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Trimethoprim.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Trimethoprim.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Trimethoprim.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Trimethoprim.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Trimethoprim.
BupropionThe metabolism of Bupropion can be decreased when combined with Trimethoprim.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Trimethoprim.
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Trimethoprim.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Trimethoprim.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Trimethoprim.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Trimethoprim.
CandesartanTrimethoprim may increase the hyperkalemic activities of Candesartan.
CandoxatrilTrimethoprim may increase the hyperkalemic activities of Candoxatril.
CapecitabineThe metabolism of Trimethoprim can be decreased when combined with Capecitabine.
CaptoprilTrimethoprim may increase the hyperkalemic activities of Captopril.
CarbamazepineThe metabolism of Trimethoprim can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Trimethoprim.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Trimethoprim.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Trimethoprim.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Trimethoprim.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Trimethoprim.
CeritinibThe serum concentration of Trimethoprim can be increased when it is combined with Ceritinib.
CeritinibTrimethoprim may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Trimethoprim.
ChloroquineTrimethoprim may increase the QTc-prolonging activities of Chloroquine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Trimethoprim.
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Trimethoprim.
CholecalciferolThe metabolism of Trimethoprim can be decreased when combined with Cholecalciferol.
CilazaprilTrimethoprim may increase the hyperkalemic activities of Cilazapril.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Trimethoprim.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Trimethoprim.
CiprofloxacinTrimethoprim may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Trimethoprim.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Trimethoprim.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Trimethoprim.
ClarithromycinTrimethoprim may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Trimethoprim can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Trimethoprim can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Trimethoprim.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Trimethoprim.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Trimethoprim.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Trimethoprim.
ClopidogrelThe metabolism of Trimethoprim can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Trimethoprim can be decreased when combined with Clotrimazole.
ClozapineTrimethoprim may increase the QTc-prolonging activities of Clozapine.
CobicistatThe metabolism of Trimethoprim can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Trimethoprim.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Trimethoprim.
ConivaptanThe serum concentration of Trimethoprim can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Trimethoprim.
CrizotinibTrimethoprim may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Trimethoprim can be decreased when combined with Crizotinib.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Trimethoprim.
CyclosporineThe metabolism of Trimethoprim can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Trimethoprim.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Trimethoprim.
DabrafenibThe serum concentration of Trimethoprim can be decreased when it is combined with Dabrafenib.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Trimethoprim.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Trimethoprim.
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Trimethoprim.
DarunavirThe metabolism of Trimethoprim can be decreased when combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Trimethoprim.
DasatinibThe serum concentration of Trimethoprim can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Trimethoprim.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Trimethoprim.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Trimethoprim.
DeferasiroxThe serum concentration of Trimethoprim can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Trimethoprim can be decreased when combined with Delavirdine.
DexamethasoneThe serum concentration of Trimethoprim can be decreased when it is combined with Dexamethasone.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Trimethoprim.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Trimethoprim.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Trimethoprim.
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Trimethoprim.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Trimethoprim.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Trimethoprim.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Trimethoprim.
DihydroergotamineThe metabolism of Trimethoprim can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Trimethoprim.
DiltiazemThe metabolism of Trimethoprim can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Trimethoprim.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Trimethoprim.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Trimethoprim.
DisopyramideTrimethoprim may increase the QTc-prolonging activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Trimethoprim.
DofetilideTrimethoprim may decrease the excretion rate of Dofetilide which could result in a lower serum level and potentially a reduction in efficacy.
DolasetronTrimethoprim may increase the QTc-prolonging activities of Dolasetron.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Trimethoprim.
DonepezilThe metabolism of Donepezil can be decreased when combined with Trimethoprim.
DopamineThe metabolism of Dopamine can be decreased when combined with Trimethoprim.
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Trimethoprim.
DoxepinThe metabolism of Doxepin can be decreased when combined with Trimethoprim.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Trimethoprim.
DoxycyclineThe metabolism of Trimethoprim can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Trimethoprim.
DronedaroneThe metabolism of Trimethoprim can be decreased when combined with Dronedarone.
DronedaroneTrimethoprim may increase the QTc-prolonging activities of Dronedarone.
DroperidolTrimethoprim may increase the QTc-prolonging activities of Droperidol.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Trimethoprim.
EfavirenzThe serum concentration of Trimethoprim can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Trimethoprim.
EliglustatTrimethoprim may increase the QTc-prolonging activities of Eliglustat.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Trimethoprim.
EnalaprilTrimethoprim may increase the hyperkalemic activities of Enalapril.
EnalaprilatTrimethoprim may increase the hyperkalemic activities of Enalaprilat.
EnzalutamideThe serum concentration of Trimethoprim can be decreased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Trimethoprim.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Trimethoprim.
EplerenoneTrimethoprim may increase the hyperkalemic activities of Eplerenone.
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Trimethoprim.
EprosartanTrimethoprim may increase the hyperkalemic activities of Eprosartan.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Trimethoprim.
ErythromycinTrimethoprim may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Trimethoprim can be decreased when combined with Erythromycin.
EscitalopramTrimethoprim may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Trimethoprim can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Trimethoprim.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Trimethoprim.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Trimethoprim.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Trimethoprim.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Trimethoprim.
EtodolacThe metabolism of Etodolac can be decreased when combined with Trimethoprim.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Trimethoprim.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Trimethoprim.
EtravirineThe serum concentration of Trimethoprim can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Trimethoprim.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Trimethoprim.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Trimethoprim.
FelodipineThe metabolism of Trimethoprim can be decreased when combined with Felodipine.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Trimethoprim.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Trimethoprim.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Trimethoprim.
FlecainideTrimethoprim may increase the QTc-prolonging activities of Flecainide.
FloxuridineThe metabolism of Trimethoprim can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Trimethoprim can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Trimethoprim.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Trimethoprim.
FluorouracilThe metabolism of Trimethoprim can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Trimethoprim.
FlupentixolTrimethoprim may increase the QTc-prolonging activities of Flupentixol.
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Trimethoprim.
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Trimethoprim.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Trimethoprim.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Trimethoprim.
FluvoxamineThe metabolism of Trimethoprim can be decreased when combined with Fluvoxamine.
ForasartanTrimethoprim may increase the hyperkalemic activities of Forasartan.
FormoterolThe metabolism of Formoterol can be decreased when combined with Trimethoprim.
FosamprenavirThe metabolism of Trimethoprim can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Trimethoprim can be increased when it is combined with Fosaprepitant.
FosinoprilTrimethoprim may increase the hyperkalemic activities of Fosinopril.
FosphenytoinThe serum concentration of Trimethoprim can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Trimethoprim.
Fusidic AcidThe serum concentration of Trimethoprim can be increased when it is combined with Fusidic Acid.
Gadobenic acidTrimethoprim may increase the QTc-prolonging activities of Gadobenic acid.
GavestinelThe metabolism of Gavestinel can be decreased when combined with Trimethoprim.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Trimethoprim.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Trimethoprim.
GemfibrozilThe metabolism of Trimethoprim can be decreased when combined with Gemfibrozil.
GemifloxacinTrimethoprim may increase the QTc-prolonging activities of Gemifloxacin.
GliclazideThe metabolism of Gliclazide can be decreased when combined with Trimethoprim.
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Trimethoprim.
GlipizideThe metabolism of Glipizide can be decreased when combined with Trimethoprim.
GlyburideThe metabolism of Glyburide can be decreased when combined with Trimethoprim.
GoserelinTrimethoprim may increase the QTc-prolonging activities of Goserelin.
GranisetronTrimethoprim may increase the QTc-prolonging activities of Granisetron.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Trimethoprim.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Trimethoprim.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Trimethoprim.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Trimethoprim.
HaloperidolTrimethoprim may increase the QTc-prolonging activities of Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Trimethoprim.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Trimethoprim.
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Trimethoprim.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Trimethoprim.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Trimethoprim.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Trimethoprim.
IbutilideTrimethoprim may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Trimethoprim.
IdelalisibThe serum concentration of Trimethoprim can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Trimethoprim.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Trimethoprim.
IloperidoneTrimethoprim may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Trimethoprim can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Trimethoprim.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Trimethoprim.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Trimethoprim.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Trimethoprim.
IndinavirThe metabolism of Trimethoprim can be decreased when combined with Indinavir.
indisulamThe metabolism of indisulam can be decreased when combined with Trimethoprim.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Trimethoprim.
IrbesartanTrimethoprim may increase the hyperkalemic activities of Irbesartan.
IrbesartanThe metabolism of Trimethoprim can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Trimethoprim.
IsavuconazoniumThe metabolism of Trimethoprim can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Trimethoprim can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Trimethoprim can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Trimethoprim can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Trimethoprim.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Trimethoprim.
KetamineThe metabolism of Ketamine can be decreased when combined with Trimethoprim.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Trimethoprim.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Trimethoprim.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Trimethoprim.
KetoconazoleThe metabolism of Trimethoprim can be decreased when combined with Ketoconazole.
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Trimethoprim.
LamivudineTrimethoprim may decrease the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Trimethoprim.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Trimethoprim.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Trimethoprim.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Trimethoprim.
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Trimethoprim.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Trimethoprim.
LenvatinibTrimethoprim may increase the QTc-prolonging activities of Lenvatinib.
LesinuradThe metabolism of Lesinurad can be decreased when combined with Trimethoprim.
LeuprolideTrimethoprim may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Trimethoprim.
LevofloxacinTrimethoprim may increase the QTc-prolonging activities of Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Trimethoprim.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Trimethoprim.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Trimethoprim.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Trimethoprim.
LisinoprilTrimethoprim may increase the hyperkalemic activities of Lisinopril.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Trimethoprim.
LopinavirThe metabolism of Trimethoprim can be decreased when combined with Lopinavir.
LopinavirTrimethoprim may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Trimethoprim.
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Trimethoprim.
LosartanTrimethoprim may increase the hyperkalemic activities of Losartan.
LosartanThe metabolism of Trimethoprim can be decreased when combined with Losartan.
LovastatinThe metabolism of Trimethoprim can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Trimethoprim can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Trimethoprim can be decreased when it is combined with Lumacaftor.
LumefantrineThe risk or severity of adverse effects can be increased when Trimethoprim is combined with Lumefantrine.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Trimethoprim.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Trimethoprim.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Trimethoprim.
MelatoninThe metabolism of Melatonin can be decreased when combined with Trimethoprim.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Trimethoprim.
MemantineThe risk or severity of adverse effects can be increased when Trimethoprim is combined with Memantine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Trimethoprim.
MercaptopurineTrimethoprim may increase the myelosuppressive activities of Mercaptopurine.
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Trimethoprim.
MestranolThe metabolism of Mestranol can be decreased when combined with Trimethoprim.
MetforminThe serum concentration of Metformin can be increased when it is combined with Trimethoprim.
MethadoneTrimethoprim may increase the QTc-prolonging activities of Methadone.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Trimethoprim.
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Trimethoprim.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Trimethoprim.
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Trimethoprim.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Trimethoprim.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Trimethoprim.
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Trimethoprim.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Trimethoprim.
MifepristoneThe metabolism of Trimethoprim can be decreased when combined with Mifepristone.
MifepristoneTrimethoprim may increase the QTc-prolonging activities of Mifepristone.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Trimethoprim.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Trimethoprim.
MitotaneThe serum concentration of Trimethoprim can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Trimethoprim.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Trimethoprim.
ModafinilThe serum concentration of Trimethoprim can be decreased when it is combined with Modafinil.
MoexiprilTrimethoprim may increase the hyperkalemic activities of Moexipril.
MontelukastThe metabolism of Montelukast can be decreased when combined with Trimethoprim.
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Trimethoprim.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Trimethoprim.
MoxifloxacinTrimethoprim may increase the QTc-prolonging activities of Moxifloxacin.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Trimethoprim.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Trimethoprim.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Trimethoprim.
NafcillinThe serum concentration of Trimethoprim can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Trimethoprim.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Trimethoprim.
NaproxenThe metabolism of Naproxen can be decreased when combined with Trimethoprim.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Trimethoprim.
NefazodoneThe metabolism of Trimethoprim can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Trimethoprim can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Trimethoprim.
NetupitantThe serum concentration of Trimethoprim can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Trimethoprim.
NevirapineThe metabolism of Trimethoprim can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Trimethoprim.
NicardipineThe metabolism of Trimethoprim can be decreased when combined with Nicardipine.
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Trimethoprim.
NicotineThe metabolism of Nicotine can be decreased when combined with Trimethoprim.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Trimethoprim.
NilotinibThe metabolism of Trimethoprim can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Trimethoprim.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Trimethoprim.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Trimethoprim.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Trimethoprim.
OfloxacinTrimethoprim may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Trimethoprim.
OlaparibThe metabolism of Trimethoprim can be decreased when combined with Olaparib.
OlmesartanTrimethoprim may increase the hyperkalemic activities of Olmesartan.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Trimethoprim.
OmapatrilatTrimethoprim may increase the hyperkalemic activities of Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Trimethoprim.
OmeprazoleThe metabolism of Trimethoprim can be decreased when combined with Omeprazole.
OndansetronTrimethoprim may increase the QTc-prolonging activities of Ondansetron.
OsimertinibThe serum concentration of Trimethoprim can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Trimethoprim.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Trimethoprim.
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Trimethoprim.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Trimethoprim.
PalbociclibThe serum concentration of Trimethoprim can be increased when it is combined with Palbociclib.
PaliperidoneTrimethoprim may increase the QTc-prolonging activities of Paliperidone.
PanobinostatTrimethoprim may increase the QTc-prolonging activities of Panobinostat.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Trimethoprim.
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Trimethoprim.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Trimethoprim.
PentamidineTrimethoprim may increase the QTc-prolonging activities of Pentamidine.
PentobarbitalThe metabolism of Trimethoprim can be increased when combined with Pentobarbital.
PerflutrenTrimethoprim may increase the QTc-prolonging activities of Perflutren.
PerindoprilTrimethoprim may increase the hyperkalemic activities of Perindopril.
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Trimethoprim.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Trimethoprim.
PhenobarbitalThe metabolism of Trimethoprim can be increased when combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Trimethoprim.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Trimethoprim.
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Trimethoprim.
PhenytoinThe metabolism of Trimethoprim can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Trimethoprim.
PimozideTrimethoprim may increase the QTc-prolonging activities of Pimozide.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Trimethoprim.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Trimethoprim.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Trimethoprim.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Trimethoprim.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Trimethoprim.
PosaconazoleThe metabolism of Trimethoprim can be decreased when combined with Posaconazole.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Trimethoprim.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Trimethoprim.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Trimethoprim.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Trimethoprim.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Trimethoprim.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Trimethoprim.
PrimaquineTrimethoprim may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Trimethoprim can be increased when combined with Primidone.
ProcainamideThe serum concentration of the active metabolites of Procainamide can be increased when Procainamide is used in combination with Trimethoprim.
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Trimethoprim.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Trimethoprim.
ProguanilThe metabolism of Proguanil can be decreased when combined with Trimethoprim.
PromazineThe serum concentration of Promazine can be increased when it is combined with Trimethoprim.
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Trimethoprim.
PropafenoneTrimethoprim may increase the QTc-prolonging activities of Propafenone.
PropofolThe metabolism of Propofol can be decreased when combined with Trimethoprim.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Trimethoprim.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Trimethoprim.
PyrimethamineThe metabolism of Trimethoprim can be decreased when combined with Pyrimethamine.
QuazepamThe metabolism of Quazepam can be decreased when combined with Trimethoprim.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Trimethoprim.
QuinaprilTrimethoprim may increase the hyperkalemic activities of Quinapril.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Trimethoprim.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Trimethoprim.
QuinineThe metabolism of Trimethoprim can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Trimethoprim can be decreased when combined with Rabeprazole.
RamiprilTrimethoprim may increase the hyperkalemic activities of Ramipril.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Trimethoprim.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Trimethoprim.
RanolazineThe metabolism of Trimethoprim can be decreased when combined with Ranolazine.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Trimethoprim.
RescinnamineTrimethoprim may increase the hyperkalemic activities of Rescinnamine.
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Trimethoprim.
RifabutinThe metabolism of Trimethoprim can be increased when combined with Rifabutin.
RifampicinThe metabolism of Trimethoprim can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Trimethoprim.
RifapentineThe metabolism of Trimethoprim can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Trimethoprim.
RiociguatThe metabolism of Riociguat can be decreased when combined with Trimethoprim.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Trimethoprim.
RitonavirThe metabolism of Trimethoprim can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Trimethoprim.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Trimethoprim.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Trimethoprim.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Trimethoprim.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Trimethoprim.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Trimethoprim.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Trimethoprim.
SaprisartanTrimethoprim may increase the hyperkalemic activities of Saprisartan.
SaquinavirTrimethoprim may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Trimethoprim can be decreased when combined with Saquinavir.
SaralasinTrimethoprim may increase the hyperkalemic activities of Saralasin.
SecobarbitalThe metabolism of Trimethoprim can be increased when combined with Secobarbital.
SelegilineThe metabolism of Selegiline can be decreased when combined with Trimethoprim.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Trimethoprim.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Trimethoprim.
SertralineThe metabolism of Sertraline can be decreased when combined with Trimethoprim.
SildenafilThe metabolism of Trimethoprim can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Trimethoprim.
SiltuximabThe serum concentration of Trimethoprim can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Trimethoprim can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Trimethoprim.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Trimethoprim.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Trimethoprim.
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Trimethoprim.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Trimethoprim.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Trimethoprim.
SorafenibThe metabolism of Trimethoprim can be decreased when combined with Sorafenib.
SotalolTrimethoprim may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Trimethoprim.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Trimethoprim.
SpiraprilTrimethoprim may increase the hyperkalemic activities of Spirapril.
SpironolactoneTrimethoprim may increase the hyperkalemic activities of Spironolactone.
St. John's WortThe serum concentration of Trimethoprim can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Trimethoprim can be increased when it is combined with Stiripentol.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Trimethoprim.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Trimethoprim.
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Trimethoprim.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Trimethoprim.
SulfisoxazoleTrimethoprim may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Trimethoprim can be decreased when combined with Sulfisoxazole.
SuprofenThe metabolism of Suprofen can be decreased when combined with Trimethoprim.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Trimethoprim.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Trimethoprim.
TamoxifenThe metabolism of Trimethoprim can be decreased when combined with Tamoxifen.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Trimethoprim.
TasosartanTrimethoprim may increase the hyperkalemic activities of Tasosartan.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Trimethoprim.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Trimethoprim.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Trimethoprim.
TelaprevirThe metabolism of Trimethoprim can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Trimethoprim.
TelavancinTrimethoprim may increase the QTc-prolonging activities of Telavancin.
TelithromycinTrimethoprim may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Trimethoprim can be decreased when combined with Telithromycin.
TelmisartanTrimethoprim may increase the hyperkalemic activities of Telmisartan.
TemazepamThe metabolism of Temazepam can be decreased when combined with Trimethoprim.
TemocaprilTrimethoprim may increase the hyperkalemic activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Trimethoprim.
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Trimethoprim.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Trimethoprim.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Trimethoprim.
TeriflunomideThe metabolism of Trimethoprim can be decreased when combined with Teriflunomide.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Trimethoprim.
TetrabenazineTrimethoprim may increase the QTc-prolonging activities of Tetrabenazine.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Trimethoprim.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Trimethoprim.
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Trimethoprim.
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Trimethoprim.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Trimethoprim.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Trimethoprim.
TicagrelorThe metabolism of Trimethoprim can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Trimethoprim can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Trimethoprim.
TocilizumabThe serum concentration of Trimethoprim can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Trimethoprim.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Trimethoprim.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Trimethoprim.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Trimethoprim.
TorasemideThe metabolism of Torasemide can be decreased when combined with Trimethoprim.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Trimethoprim.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Trimethoprim.
TrandolaprilTrimethoprim may increase the hyperkalemic activities of Trandolapril.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Trimethoprim.
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Trimethoprim.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Trimethoprim.
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Trimethoprim.
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Trimethoprim.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Trimethoprim.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Trimethoprim.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Trimethoprim.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Trimethoprim.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Trimethoprim.
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Trimethoprim.
Valproic AcidThe metabolism of Trimethoprim can be decreased when combined with Valproic Acid.
ValsartanTrimethoprim may increase the hyperkalemic activities of Valsartan.
ValsartanThe metabolism of Trimethoprim can be decreased when combined with Valsartan.
VandetanibTrimethoprim may increase the QTc-prolonging activities of Vandetanib.
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Trimethoprim.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Trimethoprim.
VemurafenibTrimethoprim may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Trimethoprim can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Trimethoprim.
VerapamilThe metabolism of Trimethoprim can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Trimethoprim.
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Trimethoprim.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Trimethoprim.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Trimethoprim.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Trimethoprim.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Trimethoprim.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Trimethoprim.
WarfarinThe metabolism of Warfarin can be decreased when combined with Trimethoprim.
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Trimethoprim.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Trimethoprim.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Trimethoprim.
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Trimethoprim.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Trimethoprim.
ZileutonThe metabolism of Zileuton can be decreased when combined with Trimethoprim.
ZiprasidoneThe metabolism of Trimethoprim can be decreased when combined with Ziprasidone.
ZiprasidoneTrimethoprim may increase the QTc-prolonging activities of Ziprasidone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Trimethoprim.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Trimethoprim.
ZuclopenthixolTrimethoprim may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Do not take calcium, aluminium, magnesium or iron supplements within 2 hours of taking this medication.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Thymidylate synthase activity
Specific Function:
Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
Gene Name:
TYMS
Uniprot ID:
P04818
Molecular Weight:
35715.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Gamarro F, Yu PL, Zhao J, Edman U, Greene PJ, Santi D: Trypanosoma brucei dihydrofolate reductase-thymidylate synthase: gene isolation and expression and characterization of the enzyme. Mol Biochem Parasitol. 1995 Jun;72(1-2):11-22. [PubMed:8538681 ]
  4. Rosowsky A, Papoulis AT, Forsch RA, Queener SF: Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim. J Med Chem. 1999 Mar 25;42(6):1007-17. [PubMed:10090784 ]
  5. Reche P, Arrebola R, Santi DV, Gonzalez-Pacanowska D, Ruiz-Perez LM: Expression and characterization of the Trypanosoma cruzi dihydrofolate reductase domain. Mol Biochem Parasitol. 1996 Feb-Mar;76(1-2):175-85. [PubMed:8920005 ]
  6. Oefner C, Parisi S, Schulz H, Lociuro S, Dale GE: Inhibitory properties and X-ray crystallographic study of the binding of AR-101, AR-102 and iclaprim in ternary complexes with NADPH and dihydrofolate reductase from Staphylococcus aureus. Acta Crystallogr D Biol Crystallogr. 2009 Aug;65(Pt 8):751-7. doi: 10.1107/S0907444909013936. Epub 2009 Jul 10. [PubMed:19622858 ]
  7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Nadph binding
Specific Function:
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.
Gene Name:
DHFR
Uniprot ID:
P00374
Molecular Weight:
21452.61 Da
References
  1. Laskowska E, Kuczynska-Wisnik D, Bak M, Lipinska B: Trimethoprim induces heat shock proteins and protein aggregation in E. coli cells. Curr Microbiol. 2003 Oct;47(4):286-9. [PubMed:14629008 ]
  2. Floris-Moore MA, Amodio-Groton MI, Catalano MT: Adverse reactions to trimethoprim/sulfamethoxazole in AIDS. Ann Pharmacother. 2003 Dec;37(12):1810-3. [PubMed:14632594 ]
  3. Rosowsky A, Fu H, Chan DC, Queener SF: Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridine s as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase. J Med Chem. 2004 May 6;47(10):2475-85. [PubMed:15115391 ]
  4. Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser PM: Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob Agents Chemother. 2004 Nov;48(11):4301-5. [PubMed:15504856 ]
  5. Barrow EW, Bourne PC, Barrow WW: Functional cloning of Bacillus anthracis dihydrofolate reductase and confirmation of natural resistance to trimethoprim. Antimicrob Agents Chemother. 2004 Dec;48(12):4643-9. [PubMed:15561838 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  2. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 02:14